Cardio Oncology Protecting Your Heart

Bridging the Gap in Cancer Care Through MyoHealth Score Guided Cardio Protection

Oncological life-saving therapies can cause subtle, progressive cardiac injury that often remains silent until significant LV dysfunction develops.
Cardiotoxicity often remains subclinical for months or years before symptoms appear, leading to heart failure  for both current and long-term survival cancer patients.

MyoHealth® helps clinicians to risk stratify, detect and monitor cardiotoxicity enabling timely cardioprotective intervention and long-term surveillance.

Clinical Applications Across the Cancer Care Continuum

  • Pre-Treatment Baseline:
    • Establishes a baseline risk score of cancer related cardiotoxicity before initiating therapy.
  • During Therapy:
    • Detects LV intramyocardial dysfunction to implement cardio protection for heart function recovery.
  • Post-Cancer Treatment and survivors:
    • Surveillance of MyoHealth Score to monitor progressive cardiac dysfunction over time
Cardio-oncology Publications

August 12, 2023

Journal of Clinical Medicine

Advances in cancer therapies have led to a global improvement in patient survival rates. Nevertheless, the price to pay is a concomitant increase in cardiovascular (CV) morbidity and mortality in this population. Increased inflammation and disturbances of the immune system are shared by both cancer and CV diseases.

Read More

June 15, 2021

Circulation: Cardiovascular Imaging

This publication features key outcome data from the PREFECT study demonstrating MyoStrain’s ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.

August 31, 2019

Abstract at ESC Congress 2019

This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.

Cardio-oncology Publications